Divided Infringement After Travel Sentry v. Tropp: Direct Infringement Liability for Third-Party Conduct

THURSDAY, MAY 24, 2018
1pm Eastern | 12pm Central | 11am Mountain | 10am Pacific

Today’s faculty features:

Thomas L. Irving, Partner, Finnegan Henderson Farabow Garrett & Dunner, Washington, D.C.
Paul W. Browning, Ph.D., Partner, Finnegan Henderson Farabow Garrett & Dunner, Washington, D.C.
Barbara R. Rudolph, Ph.D., Partner, Finnegan Henderson Farabow Garrett & Dunner, Washington, D.C.

The audio portion of the conference may be accessed via the telephone or by using your computer’s speakers. Please refer to the instructions emailed to registrants for additional information. If you have any questions, please contact Customer Service at 1-800-926-7926 ext. 1.
**Tips for Optimal Quality**

*Sound Quality*
If you are listening via your computer speakers, please note that the quality of your sound will vary depending on the speed and quality of your internet connection.

If the sound quality is not satisfactory, you may listen via the phone: dial 1-866-819-0113 and enter your PIN when prompted. Otherwise, please send us a chat or e-mail sound@straffordpub.com immediately so we can address the problem.

If you dialed in and have any difficulties during the call, press *0 for assistance.

*Viewing Quality*
To maximize your screen, press the F11 key on your keyboard. To exit full screen, press the F11 key again.
Continuing Education Credits

In order for us to process your continuing education credit, you must confirm your participation in this webinar by completing and submitting the Attendance Affirmation/Evaluation after the webinar.

A link to the Attendance Affirmation/Evaluation will be in the thank you email that you will receive immediately following the program.

For additional information about continuing education, call us at 1-800-926-7926 ext. 2.
Disclaimer

These materials have been prepared solely for educational and entertainment purposes to contribute to the understanding of U.S. intellectual property law. These materials reflect only the personal views of the authors and are not individualized legal advice. It is understood that each case is fact specific, and that the appropriate solution in any case will vary. Therefore, these materials may or may not be relevant to any particular situation. Thus, the authors and Finnegan, Henderson, Farabow, Garrett & Dunner, LLP (including Finnegan Europe LLP, and Fei Han Foreign Legal Affairs Law Firm) cannot be bound either philosophically or as representatives of their various present and future clients to the comments expressed in these materials. The presentation of these materials does not establish any form of attorney-client relationship with these authors or their firms. While every attempt was made to ensure that these materials are accurate, errors or omissions may be contained therein, for which any liability is disclaimed.
Outline

I. The *Travel Sentry* decision
   A. How it fits in the *Akamai* framework
   B. Implications of the decision

II. Other Federal Circuit Court treatment of decisions regarding divided infringement

III. Divided infringement in pharmaceutical cases

IV. Guidance on the joint infringement standard and strategies, including claim drafting, to avoid it
35 U.S.C. § 271


(a) Except as otherwise provided in this title, whoever without authority makes, uses, offers to sell, or sells any patented invention, within the United States, or imports into the United States any patented invention during the term of the patent therefor, infringes the patent.

(b) Whoever actively induces infringement of a patent shall be liable as an infringer.

(c) Whoever offers to sell or sells within the United States or imports into the United States a component of a patented machine, manufacture, combination, or composition, or a material or apparatus for use in practicing a patented process, constituting a material part of the invention, knowing the same to be especially made or especially adapted for use in an infringement of such patent, and not a staple article or commodity of commerce suitable for substantial noninfringing use, shall be liable as a contributory infringer.
Divided Infringement

- **Divided** infringement: Combined actions of multiple parties (as compared to a single party satisfying all elements of the claim).

- **Direct** infringement generally requires a single actor to practice every element of a patent claim.
  - When more than one actor practices every element, direct infringement is still possible if all steps are attributable to one person.

- **Indirect** infringement requires a showing of underlying direct infringement.
  - **Induced** infringement - one actor induces another to practice the claimed invention.
  - **Contributory** infringement - one actor contributes a material part of the claimed invention to be used by another.
Inducement: Basic Requirements

• To prove induced infringement, the patent owner must show that:

(i) there is **direct infringement**;

(ii) the accused infringer **induced** the infringement; and

(iii) the accused infringer **knew or should have known** that its actions would induce actual infringement.

  ▪ The required knowledge/scienter can be satisfied by either (i) actual knowledge of a patent **or** (ii) willful blindness to the existence of a patent.

  ▪ Requires knowledge that the induced acts constitute patent infringement and intent to cause that infringement.
Contributory Infringement:
Basic Requirements

• To prove contributory infringement, the patent owner must show that:

  (i) there is direct infringement;

  (ii) the accused infringer provides a component of a patented invention, or a material or apparatus for use in practicing a patented process which constitutes a material part of the invention;

  (iii) the accused infringer knows the component is especially made or adapted for use for infringing the patent;

  (iv) the component is not a staple article or commodity of commerce suitable for substantial noninfringing use; and

  (iii) the accused infringer knew that its actions would cause infringement.  
  ▪ Does not require intent to cause that infringement
Akamai: Setting the Stage for
Expanded Direct Infringement Liability


- Issue: Did the Federal Circuit err in holding that a defendant may be held liable for inducing patent infringement under 35 U.S.C. §271(b) even though no one person has committed direct infringement under §271(a)?

- Supreme Court unanimously reversed.
  - [I]nducement liability may arise ‘if, but only if, [there is] ... direct infringement.’”
  - Direct infringement requires one actor to perform all the claimed steps.
  - Limelight cannot be liable for inducing infringement because no single actor performed all of the claimed steps—no direct infringement.

- Supreme Court invited the Federal Circuit to revisit direct infringement
Akamai: Setting the Stage for Expanded Direct Infringement Liability

- Akamai Technologies, Inc. v. Limelight Networks, Inc., 797 F.3d 1020 (Fed. Cir. 2015) *(en banc)*

  - On remand to Federal Circuit
    - “Where more than one actor is involved in practicing the steps, a court must determine whether the acts of one are attributable to the other such that a single entity is responsible for the infringement.”

    - “We will hold an entity responsible for others' performance of method steps in two sets of circumstances:
      - (1) where that entity *directs or controls* others' performance, and
      - (2) where the actors form a *joint enterprise*.”

- Federal Circuit reversed district court’s grant of JMOL of non-infringement.
Travel Sentry, Inc. v. Tropp, 877 F.3d 1370 (Fed. Cir. 2017)

- Travel Sentry and its licensees sought summary judgment of no direct infringement of Tropp’s patents.

- Patents directed to methods of improving airline luggage inspection through the use of dual-access locks.
  - Travel Sentry sells a special lock for a customer’s luggage that can be opened by TSA using a master lock provided by Travel Sentry pursuant to a MOU.
Representative Claim: A method of improving airline luggage inspection by a luggage screening entity, comprising:

[a] making available to consumers a special lock [designed for luggage] having a combination lock portion and a master key lock portion, [and] an identification structure ...,

[b] marketing the special lock to the consumers in a manner that conveys to the consumers that the special lock will be subjected by the luggage screening entity to the special procedure,

[c] the identification structure signaling to a luggage screener ... that the luggage screening entity has agreed to subject the special lock ... to the special procedure and that the luggage screening entity has a master key that opens the special lock, and

[d] the luggage screening entity acting pursuant to a prior agreement to look for [and] upon finding said identification structure ..., to use the master key ... to, if necessary, open the ... luggage.
The actors:

[a] Travel Sentry makes the special lock available to consumers,

[b] Travel Sentry markets the special lock to the consumers,

[c] the luggage screener is signaled by the identification structure that there is a special screening procedure and master key, and

[d] the luggage screener acts pursuant to a prior agreement to look for the identification structure and to use the master key to open the luggage, if necessary.
Travel Sentry

- District Court: Summary judgment of no direct infringement of method claims
  - Travel Sentry did not control or influence or “mastermind” TSA’s performance of last two steps.
    - TSA was under no obligation to use the master keys at all,
    - MOU absolves TSA of liability for damaged locks,
    - No consequences to TSA for failure to comply with the screening process,
    - Either party can terminate unilaterally.
  - Absent direct infringement, there can be no indirect infringement.
Federal Circuit: Vacate and remand.

- Genuine disputes of material fact remain regarding whether Travel Sentry directs or controls the performance of certain steps of the claimed methods.

- Noted that where divided infringement exists, the court must determine whether the acts of one are **attributable** to the other such that a single entity is responsible for the infringement.

- Applied the 2-prong *Akamai* framework for **directing or controlling** another:
  1. Did one actor **condition participation in activity or receipt of a benefit** upon another’s performance of a claimed step?
  2. Did one actor **establish the manner or timing of performance**?
Travel Sentry

- Federal Circuit:
  
  - “[A] reasonable jury could conclude that TSA's performance of the final two claim steps is attributable to Travel Sentry such that Travel Sentry is liable for direct infringement under § 271(a).”
  
  - Common thread in conditions-participation/receipt-of-benefit cases: “evidence that a third party hoping to obtain access to certain benefits can only do so if it performs certain steps identified by the defendant, and does so under the terms prescribed by the defendant.”
Travel Sentry

- Federal Circuit acknowledged that, in Akamai, it ‘broaden[ed] the circumstances in which others' acts may be attributed to an accused infringer to support direct-infringement liability for divided infringement, relaxing the tighter constraints on such attribution reflected in our earlier precedents and in the three previous rulings for Limelight on direct infringement.’”
**Travel Sentry: District Court Errors in Akamai First Prong**

- District court “**misidentified the relevant ‘activity’ at issue**, broadly defining it as ‘the luggage screening mandated by Congress.’”
  - Federal Circuit: “the ‘activity’ in which TSA sought to participate is screening luggage that TSA knows can be opened with the passkeys provided by Travel Sentry.”

- District court “**misapprehended what types of ‘benefits’ can satisfy Akamai V’s first prong**” by finding that TSA screens luggage due to Congress, not Travel Sentry
  - Federal Circuit: a jury could find that the benefit is “the ability to open identifiable luggage using a master key, which would obviate the need to break open the lock.”
  - “The fact that TSA entered into the MOU with Travel Sentry implies that TSA believed it would receive *some* benefit from the arrangement, be it tangible (e.g., a reduction in the number of claims submitted by aggrieved travelers or an improvement in the health of its employees) or intangible (e.g., promotion of the public’s perception of the agency).”
  - “We reject the district court’s suggestion that ‘intangible benefits’ that are conditioned upon performance of claim steps are insufficient to satisfy the first prong of Akamai ....”
District court “mischaracterized what is required for one to ‘condition’ a third party's participation in an activity or receipt of a benefit on the third party's performance of one or more claim steps.”

- Federal Circuit: “a reasonable jury could conclude that Travel Sentry ‘conditions’ TSA's participation in the correctly defined activity or receipt of the correctly identified universe of benefits on TSA's performance of the final two claim steps.”

- “[W]hatever benefits flow to TSA from identifying luggage with Travel Sentry's dual-access locks and from opening these locks with the passkeys that Travel Sentry provided can only be realized if TSA performs the final two claim steps.”
Travel Sentry: District Court Errors in Akamai
Second Prong

- Federal Circuit: A reasonable jury could find that Travel Sentry established the manner or timing of TSA’s performance
  - Travel Sentry entered into the MOU with TSA, provided TSA with passkeys and instructional materials on how to identify locks licensed with Travel Sentry's trademark, and replaced passkeys.
  - The MOU sets forth the steps TSA would need to follow in order to use Travel Sentry's standard and obtain the associated benefits.
  - TSA actually used Travel Sentry's lock system.
  - Travel Sentry established its identifying mark, owns and licenses the TM to that mark and controls the design of the locks and passkeys.
**Travel Sentry: District Court Errors in Akamai Second Prong**

- **Federal Circuit:**
  - No longer apply a “mastermind” theory of liability under § 271(a).
  - “It is just as true in this case as it was in Akamai V that, if TSA ‘do[es] not follow the[ ] precise steps’ of identifying luggage bearing a Travel Sentry certified lock, and, where necessary, using the passkey provided by Travel Sentry to open said lock, then ‘[Travel Sentry's] service will not be available.’”
  - “[T]he benefits TSA allegedly seeks flow directly from its performance of the final two claim steps. This is because the very activity in which TSA seeks to participate is the very activity identified in the claim steps.”
Travel Sentry: District Court Errors in Akamai

Second Prong

• Federal Circuit:

  ▪ Even though TSA is under **no obligation** to adhere to the MOU, “TSA **cannot unlock luggage bearing Travel Sentry certified locks for screening or realize the benefits of such screening unless it performs the final two claim steps. Stated a different way, TSA only receives something of value from Travel Sentry when it performs these claim steps.**”
    — Legal obligation is not required to satisfy the second prong of Akamai;
    — TSA only receives something **of value** from Travel Sentry when it performs the last two claimed steps.

  ▪ The importance of context: Travel Sentry can stop the TSA’s ability to practice the final two claim steps by terminating the contract, failure to replace passkeys, changing the lock design.
## Travel Sentry

<table>
<thead>
<tr>
<th>Akamai test element</th>
<th>What it is</th>
<th>What it is not</th>
</tr>
</thead>
</table>
| activity            | Screening luggage under the Travel Sentry system:  
• Identifying the special locks  
• Opening special locks with a passkey | Screening luggage as per Congressional mandate |
| benefit             | • More efficient screening of luggage with the special locks  
• Ability to open locks with master key  
• Not having to break open locks  
• Fewer customer complaints  
• Improvement in employee health  
• Better PR | Screening luggage as per Congressional mandate |
| conditions          | Obtain the benefit by performing the claimed steps | Legal or contractual obligation |
| Establish manner/timing of performance | • Instruct the TSA how to perform the steps  
• Provide the TSA with the tools they need to perform the steps  
• Control whether they can or cannot perform the steps | Mastermind |
Implications of Travel Sentry

• Conditions an activity upon the performance of a claimed step.
  ▪ Defined by the terms of agreement between the parties.
  ▪ Defined with reference to the patent.
   — “These two [claimed] steps define the relevant activity in this case.”

• Conditions receipt of a benefit upon the performance of a claimed step.
  ▪ Expansive view of what constitutes a benefit.
  ▪ Intangible benefits qualify.
  ▪ Benefits may be recited in the patent specification.

• Conditions an activity or receipt of a benefit upon performance of a claimed step.
  ▪ If you perform the claimed steps, you get the benefit.
Implications of Travel Sentry

• Establish the **manner/timing of another’s performance** of the claimed steps.
  
  ▪ Instructions;
  
  ▪ No obligation required;
  
  ▪ Control.
• Post-Akamai, Pre-Travel Sentry Federal Circuit decision.
• In Medgraph, the claims were directed to a method for improving and facilitating diagnosis and treatment of patients.
  ▪ Patient data relating to medically important variables were uploaded and transmitted to a central storage device, from which they can be accessed remotely by medical professionals treating the patient.
Representative claim:

- A method for improving and facilitating diagnosis and treatment of patients having medical conditions requiring long-term profiles of specific variables, said method including the steps of
  - Using at least one measuring device [to take a measurement of a medically important variable] from a body of said patient;
  - Ensuring the patient is separated from said at least one measuring device after taking each said measurement;
  - Inputting said [variable] as raw data into a primary computer system;
  - Compiling said raw data ...;
  - Receiving a request for data [from] a medical practitioner that is treating [the patient];
  - Outputting requested data ... in the form of at least one of a chart and a graph to said medical practitioner ....
Medgraph

• Medtronic manufactures and markets the CareLink System.
  ▪ Allows patients to upload personal medical data to Medtronic’s central computer server, to keep an online record that can be accessed by patient or his physician.

• Medtronic denied direct infringement.
  ▪ CareLink system does not infringe because the claims require performance of certain steps by patients and doctors in addition to those performed by Medtronic.
    – No facts to support attribution of patient- and doctor-performed steps under the Akamai standard.

• Megraph sought a remand to reconsider direct infringement in light of the then-new Akamai decision.
Federal Circuit: Medtronic does not condition the use of, or receipt of a benefit from, the CareLink system on the performance of all of Medgraph’s method steps.

- Does not prevent users from using the CareLink system unless they perform certain of the claimed steps.
  - Does not require ensuring detachment from the measuring device.
    - Provides no incentive for such detachment.
    - Patients can use continuous glucose monitoring and still use the system.
  - Does not require synchronizing the data.
  - Does not require the physician to request the data.
    - Allows patient to bring or print data directly to physician.
Post-Travel Sentry at Federal Circuit

- **Nalco Co. v. Chem-Mod, LLC, 883 F.3d 1337 (Fed. Cir. 2018)**

  - Claim 1. A method of treating coal combustion flue gas containing mercury, comprising:
    - **injecting** a bromide compound that is a thermolabile molecular bromine precursor into said flue gas to effect oxidation of elemental mercury to a mercuric bromide and providing alkaline solid particles in said flue gas ahead of a particulate collection device, in order to adsorb at least a portion of said mercuric bromide.

  - DC: dismissed complaint alleging, *inter alia*, indirect and willful infringement.

  - FC: Reversed and remanded.
Nalco Co. v. Chem-Mod, LLC

- Defendant applies Chem-Mod Solution to coal to be supplied to furnace, argues it does not directly inject solution into flue gas

- Plaintiff alleges multiple infringement theories: direct (including divided), induced and contributory infringement

- DC: Dismissed Fourth Amended Complaint.
  - “the Chem-Mod Solution differs from the '692 Patent in both the location and method of application.”
  - No showing of intent to induce.
  - No showing of “direction and control”
    - Instructing power plants on the use of the Chem-Mod Solution insufficient to show any control over the plant’s performance of any infringing method steps.
    - Contract for purchase of the Chem-Mod Solution insufficient to establish a joint enterprise.


Nalco Co. v. Chem-Mod, LLC

Federal Circuit: Reversed and remanded.

- “Nalco met the notice requirement of FRCP Rule 8 or the pleading standard required under Twombly and Iqbal.”

- Two viable theories of direct infringement.

- “Nalco’s pleading clearly exceeds the minimum requirement under Rule 12(b)(6)[.]. Nalco met the notice requirement of FRCP Rule 8 or the pleading standard required under Twombly and Iqbal.”
**Nalco Co. v. Chem-Mod, LLC**

- Divided Infringement Claims:
  - Nalco: three ways in which performance of all steps of claim 1 can be attributed to Defendants:
    1. “Defendants operate the process that treats coal with the Chem-Mod Solution at a power plant, and then contract to provide that treated coal to the power plant.” [commercial activity - tax credits insufficient to show joint enterprise or direction or control; Federal Circuit affirmed this dismissal.]
    2. “Defendants have engaged in controlling and directing operation of a test facility in North Dakota that carries out all steps of the claim.”
    3. “Defendants directly infringed the '692 patent through full-scale testing of the Chem-Mod Solution.” Id. at 28-30.

- District court never addressed #2 or #3.
The Federal Circuit Explained that the district court had not properly applied the Akamai standard:

- “As we explained in Travel Sentry . . . Akamai “broaden[ed] the circumstances in which others' acts may be attributed to an accused infringer to support direct-infringement liability for divided infringement, relaxing the tighter constraints on such attribution reflected in our earlier precedents.”

- “Our case law emphasizes “the importance of correctly identifying the relevant ‘activity’ or ‘benefit’ that is being conditioned upon the performance of one or more claim steps. The cases also emphasize that the context of the claims and conduct in a particular case will inform whether attribution is proper under [Akamai’s] two-prong test.”

- “a common thread connects” our case law on divided infringement, no matter the relationship between the parties: we look for “evidence that a third party hoping to obtain access to certain benefits can only do so if it performs certain steps identified by the defendant, and does so under the terms prescribed by the defendant.”
Nalco Co. v. Chem-Mod, LLC

Allegations relating to pilot scale and full-scale testing plausibly state a claim that Defendants direct or control use of the Chem-Mod Solution with respect to these activities

– “Whether as part of the pilot-scale or full-scale testing, Nalco alleges that the facility conducting the test engages in a specified activity—performing each step of the methods claimed in the '692 patent as part of the testing.”

– “Nalco's pleading also alleges that performance of testing can be attributed to the actions of Defendants—this performance is conditioned on obtaining monetary benefits for performing the test requisitioned by Defendants.”

– “For the purpose of the attribution analysis, it does not matter whether the facility conducting the test is an educational facility, a non-Defendant coal-fired power plant, or a named Defendant; what matters is that, according to Nalco's allegations, the testing can be attributed to Defendants because the facility performing the test, and therein allegedly using the method described in the '692 patent, was directed to do so by Defendants.”
Nalco Co. v. Chem-Mod, LLC

- Alleged Facts also supported claims for induced and contributory infringement:
  
  - “Nalco alleged that Defendants had knowledge of the '692 patent and performed various activities with specific intent to induce others, including the Refined Coal LLCs and their coal-fired power plant customers, to infringe by, among other activities, providing instructions, support, and technical assistance for the use of the Chem-Mod Solution.

  - “Nalco alleges that Defendants have contributorily infringed the '692 patent through selling and offering to sell MerSorb and S-Sorb to operators of coal-fired power plants and/or the Refined Coal LLCs. ...Nalco contends that Defendants had knowledge of the '692 patent or were willfully blind to its existence, and that MerSorb and S-Sorb were known by Defendants to be especially made or adapted for infringing the '692 patent. ...Nalco also alleges that the Chem-Mod Solution Mixture has no substantial noninfringing uses.”
Post-Travel Sentry at District Court


  - Claim 1. A method of preparing a composition suitable to coat a tissue of a patient, the method comprising:

    - mixing reactive precursor species comprising nucleophilic functional groups, reactive precursor species comprising electrophilic functional groups, and a visualization agent such that the nucleophilic functional groups and electrophilic functional groups crosslink after contact with the tissue to form a hydrogel having an interior and an exterior, with the exterior having at least one substrate coating surface and the visualization agent being at least partially disposed within the interior and reflecting or emitting light at a wavelength detectable to a human eye to thereby provide a means for visualization of the coating by a human eye.

  - Claim 10. The method of claim 1, wherein the hydrogel forms within 5 seconds after contact with the substrate.
Motion for summary judgment that Defendant and its customers have directly infringed claim 10, and that HyperBranch is liable for induced infringement and contributory infringement of claim 10.

Plaintiff: “HyperBranch itself has performed every step of claim 10 ‘by formulating and manufacturing the Adherus products and using the Adherus products to make hydrogels while demonstrating the accused products to customers and potential customers.’”

- “the Instructions for Use included with the Accused Products teach end users to assemble and use the products to make hydrogels, and HyperBranch prepares videos showing how to prepare and apply the Accused Products.”
- In reply brief: “Defendant should be held ‘vicariously liable’ for the actions of surgeons who actually apply the Accused Products to the tissue of patients.”

Defendant: “Plaintiffs have failed to establish that ‘anyone employed by HyperBranch (or one of its distributors)’ has ever used an Accused Product and applied it to ‘the tissue’ of a patient [as required by the claim].”
Motion for summary judgment of direct infringement by Hyperbrand denied in part, granted in part.

- Applied *Travel Sentry*.

- “Under the circumstances here, it would not be equitable for the Court to grant Plaintiffs’ summary judgment based on this theory.
  - “Plaintiffs raised the vicarious liability argument for the first time in their reply brief.”
  - “the Court does not know: (1) what Plaintiffs’ theory was during the course of this litigation as to direct infringement of claim 10 (and whether, as Defendant alleges, Plaintiff did not earlier disclose the vicarious liability theory), or (2) whether Defendant had ever contended, prior to its opposition brief, that it does not infringe claim 10 because it does not directly apply hydrogel to the tissue of a patient (and if it had not, whether it should have fairly made this assertion earlier in the case).”
  - “Plaintiffs have not shown that Defendant’s employees or distributors apply the Accused Products to the tissue of a patient.”

- Granted summary judgment of direct infringement of claim 10 by customers, and induced and contributory infringement.
Eli Lilly & Co. v. Teva Parenteral Medicines, 845 F.3d 1357 (Fed. Cir. 2017)

• Claim 1. A method of administering pemetrexed disodium to a patient in need thereof comprising administering an effective amount of folic acid and an effective amount of a methylmalonic acid lowering agent followed by administering an effective amount of pemetrexed disodium, wherein the methylmalonic acid lowering agent is selected from the group consisting of vitamin B12, hydroxocobalamin, cyano-10-chlorocobalamin, aquocobalamin perchlorate, aquo-10-cobalamin perchlorate, azidocobalamin, cobalamin, cyanocobalamin, or chlorocobalamin.

• DC: No single actor performs all steps of the asserted claims, but under Akamai, direct infringement attributable to physicians and Teva liable for inducing that infringement.
  ▪ Folic acid administration performed by a patient but attributable to physicians.
  ▪ Relied in part on Teva’s proposed product labeling as evidence of infringement.
Eli Lilly & Co. v. Teva Parenteral Medicines

Teva

Supplies the pemetrexed

Patient

Self-administers folic acid

Physician

Administers B12 & pemetrexed
Eli Lilly & Co. v. Teva Parenteral Medicines

- FC: Affirmed.

- Under Akamai, “The performance of method steps is attributable to a single entity in two types of circumstances: when that entity “directs or controls” others’ performance, or when the actors “form a joint enterprise.”

- “The record is thus replete with evidence that physicians delineate the step of folic acid administration that patients must perform if they wish to receive pemetrexed treatment.”

- “the court’s finding that physicians establish the manner and timing of patients’ folic acid intake is not clearly erroneous.”

- “evidence that the product labeling that Defendants seek would inevitably lead some physicians to infringe establishes the requisite intent for inducement.”
Other Post-Akamai Decisions

- **Vanda Pharms., Inc. v. Aventisub LLC, 887 F.3d 1117 (Fed. Cir. 2018)**
  
  Claim 1. A method for treating a patient with iloperidone, wherein the patient is suffering from schizophrenia, the method comprising the steps of:
  
  - **determining** whether the patient is a CYP2D6 poor metabolizer by:
  - **obtaining** or having obtained a biological sample from the patient; and
  - **performing** or having performed a genotyping assay on the biological sample to determine if the patient has a CYP2D6 poor metabolizer genotype; and
  - if the patient has a CYP2D6 poor metabolizer genotype, then internally **administering** iloperidone to the patient in an amount of 12 mg/day or less, and
  - if the patient does not have a CYP2D6 poor metabolizer genotype, then internally **administering** iloperidone to the patient in an amount that is greater than 12 mg/day, up to 24 mg/day,
  
  wherein a risk of QTc prolongation for a patient having a CYP2D6 poor metabolizer genotype is lower following the internal administration of 12 mg/day or less than it would be if the iloperidone were administered in an amount of greater than 12 mg/day, up to 24 mg/day.
Vanda - Timeline

- Vanda’s commercial product, Fanapt®
- RE39,198, listed in OB, expired Nov. 15, 2016 (claim 3 held infringed and not invalid, determination not appealed).
- U.S. 8,586,610, listed in OB, expires Nov. 2, 2027
  - ANDA filed in 2013; only ‘198 patent listed in OB.
    - Sent para. iv notice.
- Nov. 25, 2013, Vanda asserted the ‘198 patent.
- June 16, 2014, Vanda asserted the ‘610 patent.
- Jan. 15, 2015, ‘610 patent listed in OB.
- May 6, 2015, West-Ward sent para. iv notice and amended ANDA.
- Cases consolidated.
FDA approval for iloperidone based, at least in part, on the invention disclosed in the ’610 patent, which reduces the side effects associated with QTc prolongation, enabling safer treatment of patients with schizophrenia.

“The proposed ANDA label is substantially identical in all material respects to the Fanapt® label.”
District Court: ‘610 claims infringed and not invalid.

—“West-Ward’s proposed products induce infringement ..., but do not contributorily infringe them.”

—“the proposed ANDA label “recommends”: (1) “practitioners use iloperidone to treat patients suffering from schizophrenia”; (2) “oral administration of iloperidone tablets at 12 to 24 mg/day to nongenotypic CYP2D6 poor metabolizers and 12 mg/day or less to genotypic CYP2D6 poor metabolizers”; and (3) “practitioners perform or have performed a genotyping assay to determine whether patients are CYP2D6 poor metabolizers.”
Federal Circuit: Induced infringement.

- “a patentee does not need to prove an actual past instance of direct infringement by a physician to establish infringement under 35 U.S.C. § 271(e)(2)(A).”

- ANDA infringement is hypothetical - prove that if the proposed ANDA product were marketed, it would infringe.

- Specific intent -
  - “the district court did not clearly err in finding that [the label] ‘recommends that practitioners perform or have performed a genotyping assay to determine whether patients are CYP2D6 poor metabolizers.’”
  - Does not matter if there are substantial noninfringing uses of the proposed ANDA product - “the proposed label itself recommends infringing acts.”
Guidance
Keep Enforcement in Mind When Drafting Claims

- Consider who will infringe the claims and how infringement will be proven.
- Goal: claims that will be directly and literally infringed by competitors.
- Goal: claims that will be directly and literally infringed by one actor.
  - Try to avoid divided infringement issue.
Consider How Infringement Will Be Proven

- Amgen, Inc. v. Hoechst Marion Roussel, Inc., 314 F.3d 1313 (Fed. Cir. 2003)
  
  ▪ Claim: A having a property which differs from that of A1.
  
  ▪ Specification taught three measurement methods, but failed to limit “which differs” to particular method.
  
  ▪ DC: Invalid and no infringement.
    – Patent failed to identify a single standard by which the “difference” could be measured, so patent invalid for failure to satisfy §112 and no infringement.
  
  ▪ FC: Affirmed because claims indefinite.
    – “One cannot logically determine whether an accused product comes within the bounds of a claim of unascertainable scope.”
Consider How Infringement Will Be Proven


  - Claims recited a particular "melting point elevation"
    - Art disclosed that “melting point elevation” results differed depending on which of four methods was used.
    - Patent did NOT disclose which method to use.

  - FC: claims invalid as indefinite ("insolubly ambiguous")
    - (1) a claimed property value must be determined and,
    - (2) in determining that value, several possible sample preparation methods can be used;
    - (3) the determined value changes depending on the method used; and
    - (4) the patent does not provide any direction regarding the method to be used.
Patent Claim Drafting Considerations

Why is the goal to draft claims that will be directly and literally infringed by competitors?

- Avoid difficulties of proving infringement under doctrine of equivalents.
- Deny your competitor the additional defenses to induced and contributory infringement (knowledge, intent, etc.).
- Avoid having to take extensive third party discovery, especially of your own customers or prospective customers.
Patent Claim Drafting Considerations

• Consider where infringement will occur to avoid extra-territoriality.

• Try to draft claims that will be directly and literally infringed in the U.S. by competitors.

• Try to draft claims that will be directly and literally infringed in the U.S. by one actor.
  ▪ Avoid divided infringement issue.

• A method step performed outside the U.S. may mean no direct infringement.
Example

• A method comprising reacting A with B to form C and then reacting C with D to form E.

• What if A with B to form C is performed outside of the U.S.?

• Does 35 USC §271(g) apply?
35 U.S.C. §271(g)

• [w]hoever without authority imports into the United States or offers to sell, sells or uses within the United States a product which is made by a process patented in the United States shall be liable as an infringer, if the importation, offer to sell, sale, or use of the product occurs during the term of such process patent. . . . A product which is made by a patented process will, for purposes of this title, not be considered to be so made after—

1. it is materially changed by subsequent processes; or
2. it becomes a trivial and nonessential component of another product.
Consider

• A method for reacting D with C to form E, with production of C being enabled in the specification.

• A method for reacting A with B to form C, with subsequent production of E being enabled in the specification.

• A method of forming E or C, with appropriate enablement in the specification.
Consider Where Infringement Will Occur

- *NTP, Inc. v. Research In Motion, Ltd.*, 418 F.3d 1282 (Fed. Cir. 2005)
  - No infringement of method claims where a step occurs overseas.
  - Infringement of system claims require patentee to prove that the United States is where “control of the system is exercised and beneficial use of the system obtained.”
Uniloc v. Microsoft, 632 F.3d 1292 (Fed. Cir. 2010)

- Uniloc’s ’216 patent is directed to a software registration system to deter “casual copying” of software.
- Uniloc’s system allows full use of the software (in “use mode”) only if the software installation is legitimate; otherwise, the software runs in a demonstration mode.
Example Of Claim Drafted To Avoid Extraterritoriality

Claim 19:

- A remote registration station incorporating remote licensee unique ID generating means,

- said station forming part of a registration system for licensing execution of digital data in a use mode, said digital data executable on a platform, said system including local licensee unique ID generating means, said system further including mode switching means operable on said platform which permits use of said digital data in said use mode on said platform only if a licensee unique ID generated by said local licensee unique ID generating means has matched a licensee unique ID generated by said remote licensee unique ID generating means; and wherein said remote licensee unique ID generating means comprises software executed on a platform which includes the algorithm utilized by said local licensee unique ID generating means to produce said licensee unique ID.
Drafting Specification:  
Focus On Objective Of Literal Infringement

• Specification acts as a definition for the claim terminology.

  ▪ Use specification to eliminate uncertainty.
    – Athletic Alternatives, Inc. v. Prince Manufacturing, Inc., 73 F.3d 1573, 1581 (Fed. Cir. 1996): when there is an equal choice between a broad and a narrow meaning of a claim, the public notice function is better served by interpreting the claim more narrowly.

  ▪ Use specification to describe how claims will be literally infringed.
Drafting Specification:
Focus On Objective Of Literal Infringement

- Build literal infringement by use of functional discussions, in addition to structural embodiments.

- Cascading disclosure from generic description down to preferred embodiment.
Direct Infringement: Recited Steps Can Be Satisfied by a Single Actor

- Centillion Data Sys., L.L.C. v. Qwest Commc'ns Int'l, Inc., 631 F.3d 1279 (Fed. Cir. 2011)

- Claim 1 (with numbering added to subparagraphs). A system for presenting information concerning the actual cost of a service provided to a user by a service provider, said system comprising:

  1) storage means for storing individual transaction records prepared by said service provider, said transaction records relating to individual service transactions for one or more service customers including said user, and the exact charges actually billed to said user by said service provider for each said service transaction;

  2) data processing means comprising respective computation hardware means and respective software programming means for directing the activities of said computation hardware means;

  3) means for transferring at least a part of said individual transaction records from said storage means to said data processing means;

  4) said data processing means generating preprocessed summary reports as specified by the user from said individual transaction records transferred from said storage means and organizing said summary reports into a format for storage, manipulation and display on a personal computer data processing means; means for transferring said individual transaction records including said summary reports from said data processing means to said personal computer data processing means; and said personal computer data processing means being adapted to perform additional processing on said individual transaction records which have been at least in part preprocessed by said data processing means utilizing said summary reports for expedited retrieval of data, to present a subset of said selected records including said exact charges actually billed to said user.
Direct Infringement: Recited Steps Can Be Satisfied by a Single Actor

- **Centillion Data Sys., L.L.C. v. Qwest Commc'ns Int'l, Inc., 631 F.3d 1279 (Fed. Cir. 2011)**
  
  - “Centillion concede[d] that the claim includes both a ‘back-end’ system maintained by the service provider (claim elements 1, 2, and 3) and a ‘front-end’ system maintained by an end user (claim element 4).”

- The accused products include two parts: a back office system and a front-end client application that a user may install on a personal computer. “In most uses, the processing of information on the back-end is passive. ... However, the system allows for “on-demand” reports when a user, at a personal computer, requests different date ranges. These ‘on-demand’ requests cause the back-end system to process data and deliver it to the user via download.”

- DC: summary judgment of no infringement because no single party either practiced all of the limitations of the asserted claims or controlled another party doing so.
Direct Infringement: Recited Steps Can Be Satisfied by a Single Actor

• *Centillion Data Sys., L.L.C. v. Qwest Commc'ns Int'l, Inc.*, 631 F.3d 1279 (Fed. Cir. 2011)

• FC: Vacate and remand

  • “By causing the system as a whole to perform this processing and obtaining the benefit of the result, the customer has “used” the system under §271(a). ...The customer is a single “user” of the system ....”

• Qwest does not control customers’ use.

• the user of a system who triggers operation of that system is an infringer of a claim to that system even though some elements of the system are performed by different parties.
Too often, applicants prosecute patent applications without adequately considering how the claims will be asserted in litigation, in particular, whether the patentee can proceed on a theory of direct infringement or must proceed on a theory of divided infringement.

Try to maintain originally drafted claims meeting goals of direct, literal infringement by one actor (competitor not customer).

Try to present new and amended claims meeting goals of direct, literal infringement by one actor (competitor not customer) and having written description support.

- But don’t forget your pre-AIA/AIA issues around choice of law/effective filing date if adding new claims to an application containing only claims with pre-AIA effective filing dates.
Litigation – Pleading Joint Infringement

• Requirements of Form 18.

• *Twombly/Iqbal*: “sufficient factual matter, accepted as true, to state a claim that is plausible on its face.”
  ▪ More than mere formulaic recitation of elements and conclusory legal statements.

• Plead that each and every element of claim is practiced.

• Specifically plead “direction or control” of one party over the other actors.
Litigation – Defending Against Joint Infringement Claims

• Challenge whether there is actual performance.

• Challenge whether there is “direction or control.”
Thank You!

Contact Information:

Barbara Rudolph
barbara.rudolph@finnegan.com
202.408.4346

Paul Browning
paul.browning@finnegan.com
202.408.4134

Tom Irving
tom.irving@finnegan.com
202.408.4082